Vol.

No.

April 01, 2022Apr 01, 2022

DOWNLOAD THE PDF

In an unprecedented move, Huntsman and Fred Hutch add dramatically to their catchment areas in western U.S.

Cover Story

Conversation with The Cancer Letter

In an unprecedented move, Huntsman and Fred Hutch add dramatically to their catchment areas in western U.S.

By Paul Goldberg

Cancer centers don’t usually ask NCI to increase their catchment areas. That’s because including more people and more square miles means increasing the responsibility to show impact.

White House

Biden’s FY23 proposal cuts NCI funds by $199M, while boosting ARPA-H by $4B

By Alice Tracey and Paul Goldberg

NCI Director's Report

Sharpless: You have to be an optimist to be an oncologist

By Matthew Bin Han Ong

Capitol Hill

Lowy: Paylines to stay at FY21 levels

By Alice Tracey

Free In the Archives

Cancer disruptors: When Bernie Fisher refused to grovel

In Brief

ASCO 2022 Special Awards

AACR 2022 Awards

Karen Knudsen named 2022 ResearcHERS National Ambassador

Bassel El-Rayes named deputy director of O’Neal Comprehensive Cancer Center

Albert Einstein Cancer Center appoints Ulrich Steidl, Adebola Adedimeji, H. Dean Hosgood to leadership positions

FDA seeks $8.4B to further investments in public health programs, including $20M for Cancer Moonshot efforts

Clinical Roundup

VCU and UF study: Black patients more likely to be excluded from pancreatic cancer clinical trials

Fox Chase researchers study PTEN mutations in CRC to enhance clinical targeting

Yale researchers identify accelerated genetic aging in breast tissue adjacent to breast cancer tumors

Fox Chase study: Newly defined renal neoplasm has low risk of metastasis

SKYSCRAPER-02, the first randomized study of tiragolumab in ES-SCLC, did not meet co-primary endpoint of PFS, Genentech says

Rubraca improves PFS in first-line maintenance treatment of ovarian cancer regardless of biomarker status in phase III ATHENA-MONO trial

Drugs & Targets

EU CHMP adopts positive opinion for Keytruda plus chemo ± bevacizumab in persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1)

EU CHMP adopts positive opinion for Cabometyx in radioactive iodine-refractory differentiated thyroid cancer

CHMP adopts positive opinion for Kymriah in relapsed or refractory follicular lymphoma

Thermo Fisher Scientific’s CE-IVD marked next-gen sequencing instrument available for use in clinical labs

Paige launches AI software to enable accurate and efficient detection of breast cancer metastases in lymph nodes

NCI Trials

NCI trials for April 2022

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues